SPP1 Promotes Enzalutamide Resistance and Epithelial-Mesenchymal-Transition Activation in Castration-Resistant Prostate Cancer via PI3K/AKT and ERK1/2 Pathways

Figure 1

High expression of SPP1 in prostate cancer and its relationship with survival, Gleason score, and metastatic levels. (a) SPP1 expression was analyzed in pan-cancer and was found overexpressed in multiple cancers, including PCa, breast cancer, colorectal cancer, and lung adenocarcinoma. (b) Tumor mutational burden (TMB) analysis in pan-cancer. The expression level of SPP1 was mostly correlated with TMB level with value as in PCa. (c) Disease-free survival (DFS) was significantly lower in patients who have high expression of SPP1. (d) SPP1 expression in PCa was positively associated with clinical stages. (e) SPP1 expression in PCa had a good relationship with lymph node metastasis. N0: no regional lymph node metastasis; N1: metastases in 1 to 3 axillary lymph nodes.

(a)

(b)

(c)

(d)

(e)